110 related articles for article (PubMed ID: 10595360)
21. Design of antisense and triplex-forming oligonucleotides.
François JC; Lacoste J; Lacroix L; Mergny JL
Methods Enzymol; 2000; 313():74-95. PubMed ID: 10595350
[No Abstract] [Full Text] [Related]
22. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
Saijo Y; Perlaky L; Wang H; Busch H
Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
[TBL] [Abstract][Full Text] [Related]
24. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo.
Leamon CP; Cooper SR; Hardee GE
Bioconjug Chem; 2003; 14(4):738-47. PubMed ID: 12862426
[TBL] [Abstract][Full Text] [Related]
25. Towards the selection of phosphorothioate aptamers optimizing in vitro selection steps with phosphorothioate nucleotides.
Andreola ML; Calmels C; Michel J; Toulmé JJ; Litvak S
Eur J Biochem; 2000 Aug; 267(16):5032-40. PubMed ID: 10931185
[TBL] [Abstract][Full Text] [Related]
26. In vitro transport and delivery of antisense oligonucleotides.
Hughes J; Astriab A; Yoo H; Alahari S; Liang E; Sergueev D; Shaw BR; Juliano RL
Methods Enzymol; 2000; 313():342-58. PubMed ID: 10595365
[TBL] [Abstract][Full Text] [Related]
27. Cell-specific optimization of phosphorothioate antisense oligodeoxynucleotide delivery by cationic lipids.
Williams SA; Buzby JS
Methods Enzymol; 2000; 313():388-97. PubMed ID: 10595368
[No Abstract] [Full Text] [Related]
28. Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys.
Leeds JM; Henry SP; Geary R; Burckin T; Levin AA
Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):435-41. PubMed ID: 11198927
[TBL] [Abstract][Full Text] [Related]
29. Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury.
Masarjian L; de Peyster A; Levin AA; Monteith DK
Oligonucleotides; 2004; 14(4):299-310. PubMed ID: 15665597
[TBL] [Abstract][Full Text] [Related]
30. A cytosine analog that confers enhanced potency to antisense oligonucleotides.
Flanagan WM; Wolf JJ; Olson P; Grant D; Lin KY; Wagner RW; Matteucci MD
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3513-8. PubMed ID: 10097067
[TBL] [Abstract][Full Text] [Related]
31. bis-Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver.
Bijsterbosch MK; Manoharan M; Dorland R; Van Veghel R; Biessen EA; Van Berkel TJ
J Pharmacol Exp Ther; 2002 Aug; 302(2):619-26. PubMed ID: 12130724
[TBL] [Abstract][Full Text] [Related]
32. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells.
Lisziewicz J; Sun D; Weichold FF; Thierry AR; Lusso P; Tang J; Gallo RC; Agrawal S
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7942-6. PubMed ID: 8058738
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of antisense oligonucleotides.
Agrawal S; Temsamani J; Galbraith W; Tang J
Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
[TBL] [Abstract][Full Text] [Related]
34. Antisense technologies. Improvement through novel chemical modifications.
Kurreck J
Eur J Biochem; 2003 Apr; 270(8):1628-44. PubMed ID: 12694176
[TBL] [Abstract][Full Text] [Related]
35. Development of antisense oligodeoxynucleotides for transplantation.
Stepkowski SM
Curr Opin Mol Ther; 2000 Jun; 2(3):304-17. PubMed ID: 11249625
[TBL] [Abstract][Full Text] [Related]
36. A two step model aimed at delivering antisense oligonucleotides in targeted cells.
Toth J; Boszormenyi I; Majer ZS; Laczko I; Malvy C; Hollosi M; Bertrand JR
Biochem Biophys Res Commun; 2002 Apr; 293(1):18-22. PubMed ID: 12054557
[TBL] [Abstract][Full Text] [Related]
37. Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells.
Gao WY; Storm C; Egan W; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):45-50. PubMed ID: 8423768
[TBL] [Abstract][Full Text] [Related]
38. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).
Watanabe TA; Geary RS; Levin AA
Oligonucleotides; 2006; 16(2):169-80. PubMed ID: 16764540
[TBL] [Abstract][Full Text] [Related]
39. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma.
Yu RZ; Baker B; Chappell A; Geary RS; Cheung E; Levin AA
Anal Biochem; 2002 May; 304(1):19-25. PubMed ID: 11969184
[TBL] [Abstract][Full Text] [Related]
40. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?
Eckstein F
Antisense Nucleic Acid Drug Dev; 2000 Apr; 10(2):117-21. PubMed ID: 10805163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
